Shots:

• The data includes P-l/lla study involves assessing BI-1206 + rituximab in patients with FL- MZL and MCL who have r/r to rituximab. The study demonstrated at BI-1206 is generating the first signs of clinical response in patients
• The company also presents results from two preclinical studies. The preclinical data further reinforce the efficacy and tolerability profile of BI-1206
• BI-1206 has a novel mode-of-action- acts by blocking the single inhibitory Ab checkpoint receptor FcγRIIB to unlock anti-cancer immunity in both liquid and solid tumors. The therapy is currently being evaluated in P-I/II study in combination with Keytruda & in P-I/IIa study in combination with MabThera (rituximab) for NHL

  Ref: PRNewswire | Image: Contract Pharma